OncoMatch

OncoMatch/Clinical Trials/NCT06508099

Vitamin A and D Supplementation in Allogeneic HCT

Is NCT06508099 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Vitamin A and Vitamin D3 for acute lymphoblastic leukemia.

Phase 2RecruitingSt. Petersburg State Pavlov Medical UniversityNCT06508099Data as of Jun 2026Location: Russia

Treatment: Vitamin A · Vitamin D3The therapy under investigation is the addition of 300 000 IU of vitamin A and 100 000 IU of vitamin D before conditioning. The study will include patients with malignant diseases in hematologic response with indications for allogeneic transplantation with matched related or matched unrelated donor.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Vitamin AVitamin D3

Cancer type

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Non-Hodgkin Lymphoma

Chronic Myeloid Leukemia

Myelodysplastic Syndrome

Prior therapy

Cannot have received: allogeneic transplantation of hematopoietic cells

Repeated allogeneic transplantation of hematopoietic cells

Lab requirements

Kidney function

creatinine more than 2 norms [excluded]; Creatinine clearance below 60ml/min/1.73m2 [excluded]

Liver function

ALT, AST more than 5 norms; bilirubin more than 1.5 normal [excluded]

Cardiac function

Severe cardiac pathology, including a decrease in ejection fraction <50%, unstable angina, exertional angina of III-IV functional class, heart failure of III-IV functional class, arrhythmia grade V according to Lawn [excluded]

Severe organ failure: creatinine more than 2 norms; ALT, AST more than 5 norms; bilirubin more than 1.5 normal; Creatinine clearance below 60ml/min/1.73m2; Severe cardiac pathology, including a decrease in ejection fraction <50%, unstable angina, exertional angina of III-IV functional class, heart failure of III-IV functional class, arrhythmia grade V according to Lawn

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06508099 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior allogeneic transplantation of hematopoietic cells disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify